BCIQ Profiles

Company Profile Report

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all

Read the full 284 word article

How to gain access

Continue reading with a
two-week free trial.